Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lymphodepleted autologous CD4-directed CAR T cells

A preparation of autologous peripheral blood T lymphocytes (PBTLs) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the T-cell surface antigen CD4, administered with lymphodepletion, with potential immunostimulating and antineoplastic activities. Upon administration, lymphodepleted autologous CD4-directed CAR T cells specifically recognize and kill CD4-expressing tumor cells. CD4, a tumor-associated antigen (TAA), is overexpressed in various lymphomas, including peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous LCAR-T2C CAR-T cells
autologous LCAR-T2C CAR-T lymphocytes
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search